Abstract
Frank Fan, Brock Binkowski, Susan Wigdal, Braeden Butler, Ken Lewis, Pete Stecha, Keith Wood
Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711
Many potentially druggable targets have proven to be difficult to adapt to many screening programs, especially as cell-based assays. In recent years we have developed new bioluminescent-based assays to address such challenges. Bioluminescent assays are uniquely suited for high-throughput screening due to their inherent high sensitivity, wide dynamic range and low susceptibility to compound interference. In this report, we present a new biosensor technology to address two popular targets in pharmaceutical screening: Proteases and GPCRs.